AbbVie is scheduled to report third-quarter 2026 results on October 30, with consensus estimates projecting global Rinvoq net revenues near $2.73 billion, reflecting about 25% year-over-year growth from the prior period. This outlook stems from sustained demand across approved immunology indications, recent European approvals for vitiligo and alopecia areata, and ongoing U.S. label expansions under review. Analysts, including RBC, highlight Rinvoq alongside Skyrizi as key drivers of potential top-line outperformance, supported by market-share gains that have offset Humira erosion. Q2 results showed Rinvoq at $2.525 billion, up 24.5%, providing a solid base rate, though intensifying competition from agents like Tremfya and Omvoh introduces some uncertainty around exact sequential trends. Traders are monitoring these dynamics ahead of the earnings release for resolution signals.